What is keeping the priced down is simply lack of
Post# of 155159
(Total Views: 380)
Posted On: 11/22/2019 2:26:31 PM
What is keeping the priced down is simply lack of investors willing to run the risk and the periodic availability of shares via noteholders and raises.
The lack of buying investors will be solved once the news “hits the press” and/or CYDY is up-listed, in the side of “risky” investors one has to agree that if somebody wants to buy the stock the first question is: shall I buy now or latter as there are periodic dilutions and the price might go down before it goes up?. Is a valid question.
Some will just wait until the stock probes itself and “all is safe”. That is fine. I personally prefer to buy at the bottom once my DD tells me that the science is there simply because the potential of gain is much larger. Won’t bother you with the risk/reward stuff.
The problem is what is the bottom
and, more to the point: WHEN is it. Nobody knows and if somebody knew wouldn’t be wasting time here simply because it will be millionaire many times over by now.
My “bottom” has been wrong many times (including this time), but, am I a loser? No, because providing the price goes above the bottom sometime I will be just fine.
Regarding the deal announcement: Once this happens the second class of investors, those that are delaying jumping in due to concerns about further weakness in the stock will enter the fray as this risk will largely disappear. Also, the community at large will learn that another company is betting in the drug (a drug) being a reality, more exposure will follow.
How high will the SP raise to? Let me state the obvious: depends on how many people start buying . However, IMHO if the price does not approach the fair valuation for the combo, I will see it as another opportunity to add-up. The stock price should reflect not only the current condition to be marketed, but the potential of the drug for others. But again, the price will reflect only the appetite of investors for the stock at any given time. Which is good because our appetite is better than theirs and we are right the “fat cats” will be us. Meaning we will profit and they will “feed the market”.
So the price should not be a mere $1 after the announcement (we will have a de-risked product with a de-risked commercialization with de-risked financing). But, again, you might be right if there are not enough of us willing to buy something that seems too good to be true.
This is the market itself, some see the opportunities, some don’t, but I think we are in the right side of the fence. Let's try to be calm and cool in spite of our COD (possible?).
The lack of buying investors will be solved once the news “hits the press” and/or CYDY is up-listed, in the side of “risky” investors one has to agree that if somebody wants to buy the stock the first question is: shall I buy now or latter as there are periodic dilutions and the price might go down before it goes up?. Is a valid question.
Some will just wait until the stock probes itself and “all is safe”. That is fine. I personally prefer to buy at the bottom once my DD tells me that the science is there simply because the potential of gain is much larger. Won’t bother you with the risk/reward stuff.
The problem is what is the bottom
and, more to the point: WHEN is it. Nobody knows and if somebody knew wouldn’t be wasting time here simply because it will be millionaire many times over by now. My “bottom” has been wrong many times (including this time), but, am I a loser? No, because providing the price goes above the bottom sometime I will be just fine.
Regarding the deal announcement: Once this happens the second class of investors, those that are delaying jumping in due to concerns about further weakness in the stock will enter the fray as this risk will largely disappear. Also, the community at large will learn that another company is betting in the drug (a drug) being a reality, more exposure will follow.
How high will the SP raise to? Let me state the obvious: depends on how many people start buying . However, IMHO if the price does not approach the fair valuation for the combo, I will see it as another opportunity to add-up. The stock price should reflect not only the current condition to be marketed, but the potential of the drug for others. But again, the price will reflect only the appetite of investors for the stock at any given time. Which is good because our appetite is better than theirs and we are right the “fat cats” will be us. Meaning we will profit and they will “feed the market”.
So the price should not be a mere $1 after the announcement (we will have a de-risked product with a de-risked commercialization with de-risked financing). But, again, you might be right if there are not enough of us willing to buy something that seems too good to be true.
This is the market itself, some see the opportunities, some don’t, but I think we are in the right side of the fence. Let's try to be calm and cool in spite of our COD (possible?).
(4)
(0)